Needham analyst Joseph Stringer maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $80 price target.
Needham Maintains Buy on Apellis Pharmaceuticals, Maintains $80 Price Target
Needham analyst Joseph Stringer maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $80 price target.
Related Posts
Novartis Announced Kisqali Adds One More Year of Survival Benefit for Broadest Set of Patients, Including Those with Aggressive HR+/HER2- Advanced Breast Cancer
Novartis today announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC)1.
Why Chewy Stock Hit A New All-Time Low Today
Chewy Inc (NYSE: CHWY) shares are trading lower by 4.5% to $18.57 Wednesday morning after Oppenheimer analyst Rupesh Parikh downgraded shares from Outperform to Perform.
Why Paramount Global Stock Is Moving Lower Wednesday
The CBS News report from Tuesday suggests that National Amusements, which controls Paramount, ended merger discussions with Skydance.